Emmaus Life Sciences Provides Update in Response to the Coronavirus (COVID-19) Pandemic

TORRANCE, Calif., March 24, 2020 (GLOBE NEWSWIRE) — Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease (SCD) treatment, announced today several steps it has taken in response to the Coronavirus (COVID-19) pandemic. Within the overall SCD community, Emmaus is working in coordination with the Sickle Cell Disease Association of America and other organizations to educate and communicate with the SCD community during this challenging time. For more information, please visit:?https://www.sicklecelldisease.org/2020/03/17/health-alert-for-patients-and-caregivers/